Xin Lang Cai Jing·2025-09-17 09:13Core Viewpoint - The article discusses significant legal developments regarding investor compensation lawsuits against Dingxin Communications (603421) and Sichuang Medical (300078) due to false statements and financial misconduct [1][2]. Group 1: Dingxin Communications (603421) - Dingxin Communications has been ordered by the Shandong High Court to pay a total of 32,800.75 yuan in a lawsuit related to false statements, following a previous ruling by the Qingdao Intermediate People's Court [1]. - The company failed to timely disclose significant changes in external conditions affecting its operations, specifically regarding the State Grid's procurement freeze, which had a major impact on its revenue [1]. - The company also did not disclose the disposal of shares by its controlling shareholder and actual controller, which is another basis for potential investor claims [2]. Group 2: Sichuang Medical (300078) - The investor compensation case against Sichuang Medical is ongoing, with a lawsuit filed in Wenzhou Intermediate Court, following previous successful claims by investors [2]. - The company has been found to have fabricated significant false information in its public offering documents and had false records in its annual reports for 2019 and 2020 [3][4]. - Investors who purchased Sichuang Medical shares between April 30, 2020, and October 29, 2022, may still initiate claims, as the case is approaching the statute of limitations [5].